Redeye provides an initial take following Paxman’s Q4 2025 report. The report did not live up to our expectations, with sales coming in 7% below our estimate. We will publish a research update with a more detailed review of the report. We expect to revise our sales estimates downwards, which will most likely result in a lower valuation of the company.
LÄS MER
